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Effects of Increased Drug Copayments on the Demand for Drugs and
Physician Visits in Germany
Gerald Schnell, Afschin Gandjour, Karl W. Lauterbach
Background: On July 1, 1997, the German government raised drug copayment by € 2.60 to € 4.60,
€ 5.60 or € 6.60 per prescription, depending on package size. The aim of this study was to examine
the effects of increased copayments on the demand for drugs and physician visits one year later.
Lower income groups and the chronically ill were analysed separately.
Methods: A survey of 695 non-exempted adult pharmacy customers who suffered from acute or
chronic health conditions in the previous 12 months was conducted. Logistic regression was per-
formed to analyse the effect of different income levels on the demand for drugs and physician visits.
Results: Of the respondents, 19.9% reported reduced physician visits, 22.6% reported reduced pre-
scription drug purchases, 44.9% reported increased use of over-the-counter products and 46.3% re-
ported increased use of non-drugs such as household remedies. A total of 11.2% waived more than
one visit to the physician. Almost all of those respondents who reduced their purchases of prescrip-
tion packages waived 1 to 5 packages (82.5%). There was distinctly less change in purchasing pat-
terns among persons with chronic diseases. Logistic regression confirmed that lower income house-
holds were more likely to change demand patterns than households in other income brackets.
Conclusion: Increased copayments had little effect on drugs and physician visits of adult pharmacy
customers, especially among those with chronic conditions. Negative effects on low income house-
holds were observed.
Introduction
Germany has faced growing health care expenditures for many years. As a percentage of gross do-
mestic product (GDP), medical spending increased from 8.7 % in 1990 to 10.6 % in 1998 and 10.9 %
in 2002 [1]. This is a higher percentage of gross domestic product than in almost all other industrial-
ised countries, surpassed only by the United States and Switzerland. A great part of these costs is cov-
ered by Germany’s statutory health insurance, which provides health coverage for about 87 % of the
German population. One of the important cost drivers is expenditures for prescribed drugs. Prescrip-
tion drug expenditures covered by statutory health insurance amounted to € 18.3 billion in 1998 [2],
which is about 14.3 % of the total spending [3].
To offset rising costs, several cost-containment instruments have been implemented in the pharma-
ceutical market over the last decade. On July 1st, 1997, after years of much smaller increases, drug
copayment was increased by € 2.60 to € 4.60, 5.60 or € 6.60, depending on the package size.
The decision to increase drug copayments was met with great concern among Germans. The govern-
ment was criticised for discriminating against the poor and the chronically ill. The government ar-
gued that they expected copayments to have only financial effects, meaning a shift in costs from the
statutory health insurance fund to drug users. To ensure this, the government introduced maximum
copayments for the chronically ill [4]. Exemptions for low income groups and a maximum
copayment level had already been in existence. Physician visits remained free of charge.
Several studies in other health care systems show that even small copayment levels have a significant
impact on the use of drug prescriptions. Studies in the U.S. for different settings, ages and income
groups [5-10] and the RAND Health Insurance Experiment [11-12] found that increasing drug cost
sharing decreased prescription drug usage. These findings are supported by studies from the U.K.
[13-15] and Canada [16-17]. Altogether, however, drug use is rather inelastic. Price elasticity varies
mostly from –0.1 to –0.3. That means that when the copayment charge is increased by 60%, the num-
ber of prescriptions is reduced by 6% to 20%.
Some studies have produced more detailed information about whether copayment has different ef-
fects on necessary or discretionary drugs. They considered drugs necessary if they were used for
chronic conditions, e.g., antihypertensive agents, diuretics or antidiabetics. Drugs like cold remedies
or sedatives were defined as discretionary drugs, used in acute conditions. The results are ambiguous.
Johnson et al. [18] could not find a consistent pattern when copayments were increased each year
over a three-year period. Harris et al. [6] showed that discretionary drugs were more affected. Reeder
and Nelson [19] found decreased use of cardiac agents, diuretics, psychotherapeutics and
cholinergics, whereas other classes of drugs, such as analgesics or sedatives, were not affected.
There is also the question of possible substitution effects. Stuart and Grana [20] found that
over-the-counter drugs (OTC) and prescription drugs (RX) are economic substitutes; whereas
Leibowitz [21] showed that patients with full insurance coverage used both over-the-counter drugs
and prescription drugs more than patients with a co-insurance policy.
The impact of drug copayments on physician visits was examined by Johnson et al. [8], who found no
effect on an elderly population. There is little evidence that the impact on a low-income population is
greater than on a high-income population. Only Foxman et al. [22] were able to show that antibiotic
use decreased most in the lowest third of the income distribution when patients had to pay a co-insur-
ance fee of 25% or more.
It is difficult to generalise these results to the situation in Germany. No study has been published yet
on different age groups and patients of different working status. Previous studies dealt either with the
elderly or the work force. Further, the existence and direction of substitution effects is not clear, and
effects on different income groups are rather small.
The present study was conducted to examine the effect of increased copayments in the German health
care system. First, our goal was to find out if non-exempted persons changed their demand for drugs
and medical services. We wondered if individuals avoided physician visits and/or had fewer pre-
scriptions dispensed. Further, we wanted to know if patients tried to influence the physician’s pre-
scribing, e.g. by requesting a larger package size to reduce the amount of copayment per tablet. We
also wanted to know if patients substituted over-the-counter drugs products, household remedies or
alternative health care services for prescription drugs. Moreover, we wanted to find out if patients
with chronic conditions were influenced by the increased copayment in their demand for drugs and
medical services. Finally, we wanted to analyse the impact of copayments on households in different
income brackets.
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METHODS
Study design
The study was conducted in Cologne, a city with 1 million inhabitants, from October to December
1998. Questionnaires were distributed to 68 pharmacies (23% of all pharmacies) in Cologne. In-
cluded were non-exempted patients who experienced acute or chronic health problems in the last 12
months.
We chose a convenience sampling method. Postage prepaid questionnaires were displayed on the
desk of the pharmacy where visitors could pick them up. The questionnaires were completed at home
and mailed back to the institute. A pilot study demonstrated the feasibility of the questionnaire and
the sampling method.
Sample
About 87% of the population in Germany was covered by statutory health insurance at that time.
Most of the population was charged for drug prescriptions, both for brand and generic drugs. Patients
younger than 18 years of age were exempt from copayment charges. They accounted for about 19%
of those covered by statutory insurance. Further exempted was the lowest income group. It included
mainly social security recipients as well as those among the statutorily insured who had gross earn-
ings of less than € 873 (single), € 1,201 (married) or € 1,427 (married plus 1 child) per month (all fig-
ures are for 1997). In 1997, this group accounted for another 14% of the statutorily insured. There-
fore, about 67% of the insured were subjected to drug copayments [2]. Further, a ceiling of 2% of the
gross family income was imposed. This fee was reduced for the chronically ill in the second year of
their disease. It is estimated that 60,000 people or about 0.1% of the statutorily insured made use of
this exemption in 1998.
Data
A written questionnaire was developed for patient completion. In the first part of the questionnaire,
respondents were asked to provide socio-demographic information. The questions in the second part
were about the existence of acute or chronic conditions and health care utilisation within the last 12
months. In the third section, we asked respondents whether or not copayment caused changes in their
demand for health care in the last 12 months. The final section asked the chronically ill about any
changes in their demand for health care relating to their chronic condition.
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Model and Variables
Through the survey, we asked individuals if the increased copayment had caused changes in their de-
mand patterns over the last 12 months. We chose five variables to measure changes in demand pat-
tern: reduced prescription purchases, reduced physician visits, increased non-drug use, increased use
of OTC products and increased requests for less expensive prescriptions. We described increased
non-drug use as household remedies such as teas and alternative medical care such as homeopathic
services and acupuncture. We dealt with the topic of increased requests for more economic prescrip-
tions in five questions, which took the costs of the prescriptions into consideration: this included re-
quests for cheaper or for no prescriptions, for a larger or smaller package size or for alternative medi-
cal care. Answer possibilities were “once”, “several times” and “no”.
We used a logistic regression model to analyse the effect of different income levels on the variables,
and defined income as the net annual household income per capita. The model adjusted for differ-
ences in socio-economic and other characteristics. Explanatory variables were age, gender, educa-
tion, number of information sources used, existence of additional private insurance, number of physi-
cian visits in the last 12 months, OTC drugs consumed in the last 12 months, amount of copayments
in the last 12 months, and the existence of acute and chronic conditions. We classified gender as a
dummy variable with women equal to 1. Income was adjusted by household size as follows. Seven
income classes were given as answer categories. Under the assumption of a normal distribution
within each income class, the midpoint of each class was divided by the number of household mem-
bers. In this way we derived household income per capita in € per month. Education was measured by
the number of years of formal schooling. In order to facilitate the response, we used 4 to 5 intervals to
estimate the number of physician visits, number of days drugs were consumed and amount of
copayments in the last 12 months. Calculations were again done with class midpoints. Patients faced
with a chronic condition were asked about their medication used. An individual consuming drugs
minimum of 3 times a week was defined as chronically ill. Frequent chronic conditions which are
usually treated by medication, such as high blood pressure, heart problems, high cholesterol level,
asthma or diabetes mellitus, were given as answer possibilities.
Statistics
We conducted binary logistic regression with each of the five dependent variables. The method we
used is described by Hamilton [23]. Therefore, we summarised the answer possibilities “once” and
“several times” of the dependent variables to “yes”. In this way we could be sure that both answer cat-
egories contained enough cases to get robust results. We tested variables for multicollinearity.
Studentized residuals checked for outliers. To identify influential cases, we used Cook’s Distance.
We used the likelihood ratio test to confirm the hypothesis that the model showed no overall effect.
We calculated the t statistic and the p value for each variable. Significance level was α = 0.05.
When we asked about the number of visits to a physician in the last 12 months, we facilitated the esti-
mation for high drug users by giving a 3-month period as an additional answer possibility. The esti-
mation on a 3-month period was then extrapolated to a 12-month period. Of the respondents, 54 did
not answer the question concerning the 12-month time period. In order to interpolate 53 of these
missing values, we did linear regression using the variables number of visits in the last 3 months and
chronic condition. R2 was 59%. We did the same for the amount of copayments in the last 12 months,
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where 100 values were missing. Explanatory variables were the amount of copayment charged in the
last 3 months, age, number of physician visits, number of information used and gender. R2 was 70%.
RESULTS
Table 1.    Characteristics of All Respondents and of Respondents Included in the Regression
Analysis (Subsample)
Personal Characteristics All Subjectsa
(n = 695)
Subsample
(n = 605)
Mean age (yr.) 54.6 53.8
Female (%) 64.2 64.0
Additional private insurance (%) 22.6 23.0
Average household size (members) 2.0 2.0
Household income (net) (%)
< € 920 7.9 6.4
€ 920 - € 1,278 19.5 19.0
€ 1,278 - € 1,534 21.0 21.7
€ 1,534 - € 2,045 20.3 20.3
€ 2,045 - € 2,556 13.7 14.5
€ 2,556 - € 3,068 8.4 8.4
> € 3,068 9.3 9.6
Education (%)
Education less than Baccalaureate 66.8 64.0
Baccalaureate 13.2 14.2
University degree 19.9 21.8
Acute condition in the last twelve months (%) 67.8 68.1
Chronic condition in the last twelve months (%) 58.4 59.8
Physician visits in the last twelve months (%)
0 1.4 1.3
1 - 5 37.9 38.5
6 – 10 33.4 32.9
11 –20 13.3 14.5
> 20 14.0 12.7
a Percentages among respondents were calculated.
In total, 742 questionnaires were sent back. We excluded 22 questionnaires which were not com-
pleted correctly, 24 respondents who were covered by private insurance and 1 respondent younger
than 18 years of age. We used a sample of 695 questionnaires for our descriptive analysis. We ex-
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cluded 90 questionnaires because of missing values. Thus, we did logistic regression with the 605
complete questionnaires. Characteristics of included and excluded patients were very similar (Table
1). The mean age of the respondents was 55 years, and 64% of respondents were women.
Table 2 shows the results regarding the impact of increased drug copayment on the demand for drugs
and physician visits. About 22.6% of the respondents reported that they had waived a prescription
once or several times. We asked these respondents about the number of prescriptions they had
waived. Most of them (82.5%) answered that they had not bought 1 to 5 drugs, and 10.4% had waived
5 to 10 drug prescriptions.
Table 2. Effects of Increased Drug Copayment on the Demand for Drugs and Physician Visits
(n = 695)
Effects of Increased Drug Copayment in %
Reduced physician visits 19.9
Reduced drug purchasesa 22.6
Increased requests for more economic prescriptionsa 49.7
Increased non-drug use 46.3
Increased use of OTC products 44.9
a Only physician visitors (n = 680)
About 19.9% of the respondents reported that they had avoided at least one physician visit in the last
year because of increased copayments. Of these respondents, 8.6% reported that they had renounced
one visit, the other 11.2% had renounced more than one visit. To get an impression about the range of
changes, we made a rough estimation about the impact on physician visits on the basis of the number
of physician visits in the last year reported by each respondent. Patients answering “more than one
visit” waived at least 2 visits. This results in a reduction of at least 4% of physician visits per year by
the non-exempted insured.
During a physician visit, 49.7% of the respondents reported that they had specific requests concern-
ing the prescription. Most of the respondents said that they asked for the prescription of a larger pack-
age size (35.4%). The respondents requested another, cheaper prescription (17.1%), a smaller pack-
age size (5.6%) or alternative medical care instead of medication (7.9%). Only a small portion of the
respondents, 4.9%, told the physician not to prescribe any drugs. Finally, more than 40% reported an
increase of OTC products and non-drug use to treat less serious diseases.
16 soFid Gesundheitsforschung  2005/1
Effects of Increased Drug Copayments on the Demand for Drugs and Physician Visits...
Table 3. Distribution of Chronic Diseases among the Chronically Ill (n = 406)
Chronic Diseases in %
Hypertension 36.7
Heart failure 23.4
High cholesterol level 19.0
Thyroid dysfunction 18.5
Risk of osteoporosis 15.5
Obesity 14.0
Diabetes mellitus 11.6
Asthma 9.4
Other chronic diseases 39.9
In the second section of the questionnaire, we asked similar questions of patients suffering from one
or more chronic conditions about the treatment of their chronic disease. Table 3 shows the distribu-
tion of the diseases. We found that the impact of increased copayment on the treatment of chronic dis-
eases was less pronounced among the chronically ill than among respondents as a whole. Table 4
shows the results. Only about 6% to 7% of the chronically ill reported reduced physician visits and re-
duced drug purchases.
Table 4. Effects of Increased Drug Copayment on the Chronically Ill (n = 406)
Effects of Increased Drug Copayment in %
Reduced physician visits 6.2
Reduced drug purchases 6.7
Increased non-drug use 15.0
Increased use of OTC products 10.1
Reduced drug consumption 8.6
Changed drug consumption 3.9
Request for the prescription of fewer drugs 3.7
Increased copayment had no effect 67.2
Finally, we wanted to know if drug copayment had a stronger effect on lower income households. Ta-
ble 5 shows the results of the logistic regression. We detected no influential outliers. Odds ratios of
the logit-functions and confidence intervals are reported in the table. An odds ratio of less than one
indicates that the independent variable, e.g. household income per capita, has a negative effect on the
dependent variable, e.g. reduced physician visits. The more the household income per capita in-
creases, the higher the likelihood that the copayment causes the individual to reduce the number of
physician visits decreases.
soFid Gesundheitsforschung  2005/1 17
Effects of Increased Drug Copayments on the Demand for Drugs and Physician Visits...
Table 5. Odds Ratios and 95% Confidence Intervals for Effects of Increased Drug Copayment
(n = 605)
Reduced
physician visits
Reduced
prescribed drug
purchases
Increased
requests for
more economic
prescriptions
Increased use of
OTC products
Increased
non-drug use
Household income
per capita
0.5677***
(0.4252; 0.7581)
0.6821**
(0.5299; 0.8781)
0.7095***
(0.5851; 0.8604)
0.9077
(0.7580; 1.0870)
0.7313**
(0.6034; 0.8862)
Education 0.9664
(0.8995; 1.0384)
0.9557
(0.8954; 1.0201)
1.0103
(0.9566; 1.0671)
0.9219**
(0.8728; 0.9738)
0.9296**
(0.8805; 0.9814)
Gendera 1.4041
(0.8645; 2.2804)
1.2727
(0.7939; 2.0403)
1.3203
(0.8968; 1.9439)
1.6317*
(1.1211; 2.3747)
2.0061***
(1.3723; 2.9327)
Age 0.9908
(0.9748; 1.0072)
0.9537***
(0.9382; 0.9695)
1.0033
(0.9902; 1.0167)
0.9926
(0.9798; 1.0055)
1.0096
(0.9966; 1.0227)
Amount of
copayment paid
1.0015*
(1.0001; 1.0031)
1.0014
(1.0000; 1.0029)
1.0023***
(1.0011; 1.0035)
0.9998
(0.9986; 1.0009)
1.0014*
(1.0002; 1.0026)
OTC products
consumed
1.0187
(0.9929; 1.0452)
1.0071
(0.9819; 1.0330)
1.0245*
(1.0030; 1.0465)
1.0598**
(1.0375; 1.0825)
1.0092
(0.9885; 1.0303)
Physician visits 0.9580*
(0.9230; 0.9944)
1.0041
(0.9698; 1.0396)
1.0009
(0.9714; 1.0313)
0.9904
(0.9619; 1.0197)
0.9733
(0.9453; 1.0022)
Acute condition 2.9013***
(1.6450; 5.1171)
1.4668
(0.8962; 2.4007)
1.4008
(0.9484; 2.069)
1.2100
(0.8258; 1.7731)
1.4671*
(1.0012; 2.1497)
Chronic condition 0.8421
(0.5014; 1.4144)
0.8199
(0.5034; 1.3355)
1.6214*
(1.0642; 2.4704)
0.8267
(0.5452; 1.2533)
0.9164
(0.6035; 1.3917)
Additional private
insurance
0.5376*
(0.2964; 0.9748)
1.0427
(0.6308; 1.7233)
1.1163
(0.7290; 1.7093)
0.9735
(0.6414; 1.4776)
0.7608
(0.5004; 1.1566)
No. of information
sources
0.9836
(0.8245; 1.1734)
1.0631
(0.8984; 1.2579)
1.1379
(0.9841; 1.3156)
1.1308
(0.9821; 1.3019)
1.1254
(0.9781; 1.2949)
*** p < 0.001   ** p < 0.01   * p < 0.05 a women = 1
We found a strong negative correlation between the likelihood to change drug demand and the per ca-
pita household income. Four of the five models show significant effects. Patients with lower income
were more likely to reduce drug purchases (p<0.01) than those with a higher income. They were also
more likely to reduce physician visits (p<0.001), to discuss the possibility of a more economic pre-
scription with the physician (p<0.001) and to increase non-drug use (p<0.01).
Further, we found that other explanatory variables were associated with an increased likelihood to
change drug demand. Women and less educated people were more likely to increase non-drug and
OTC-product use. Younger people were more likely to discuss prescriptions alternatives with a phy-
sician. Patients with high copayments and OTC products consumed were more likely to change their
demand patterns. However, copayment caused patients with a small number of physician visits to re-
duce them. When there was an acute condition, physician visits were reduced and non-drug use in-
creased. Patients with chronic conditions discussed prescription alternatives with the physician,
mainly regarding larger package sizes.
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DISCUSSION
The results of the survey show that increased drug copayment had a slight effect on the demand for
drugs and physician visits for a great number of pharmacy customers, mainly in the treatment of
acute conditions. Lower income households were more likely to change their demand patterns than
households in higher income brackets.
Our study sample included non-exempted patients who developed chronic and acute health problems
within the last year. This broad study sample included all potential drug users who were faced with
prescription fees.
The study is limited by the data collection method. We did not directly ask pharmacy customers to
participate, but left it to the discretion of visitors to pick up a questionnaire. Therefore, a response rate
cannot be determined. To ensure that the sample was not atypical, we compared the characteristics of
the respondents with those of respondents to another survey conducted one year before in Cologne
and the greater Cologne area [24] as well as the normal population of Cologne. This survey was also
conducted in pharmacies. The sample included all pharmacy visitors, with no exclusion criteria
given. 18,693 forms were evaluated. We found a strong congruence between the baseline character-
istics of participants of both studies. Our respondents were slightly younger (+3.4% in the group
31-60 years of age and -5.2% in the group older than 60 years of age) and were made up of fewer
women (- 6%). Our sample had a lower representation in the income class of households with more
than 5,000 DM per annum (17.6% vs. 21.6%). When compared to the demographics of the popula-
tion of Cologne, single-person households were underrepresented in our sample. The income distri-
bution showed that our sample had a smaller percentage of respondents from the lowest income class
(< 1,800 DM) than is representative of the German population, a divergence which is congruent with
the exemption rule. Our respondents were on average more educated than the German population as a
whole, which can be explained by the study location in an urban region and the correlation between
the exempted low-income patients and their low education level. Nevertheless, we cannot fully ex-
clude the possibility that there is a systematic correlation between the willingness to fill in the ques-
tionnaire and the reaction to drug copayment.
Surveys are limited by the accuracy of the reported data. Response biases such as respondents’ ten-
dencies to answer a question with “yes” or to answer in a socially desirable manner cannot be ex-
cluded. Further, it is known that individuals underreport health service use when asked to recall a
12-month period [25-26]. However, there is no evidence that underreporting varies systematically by
respondents’ characteristics, e.g. gender, age or income level. Assuming that the recall bias affects all
respondents similarly, descriptive results and results from the regression analysis are not biased by
the tendency to underreport health services. To reduce potential biases, answer classes were given,
and the exact number was not asked. Regression analysis only distinguished those who changed their
demand from those who did not.
We compared our results with total drug sales and total number of drugs consumed by the population
covered by statutory health insurance. There are no data available that refer to drug use for those who
are charged for their prescriptions. Figure 1 shows the development in the prescription sales market
since 1994. Between 1994 and 1996, no additional regulation was conducted by the government to
influence drug expenditures. The number of prescriptions sold per year varied by 3% to 6%. In 1997,
there was a decrease of 11%, followed by another decrease of 3% in 1998; whereas, the number of
patients insured decreased by only 0.5% [3]. Copayment had been increased by 1 DM (0.51 EUR) on
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January, 1st 1997, other regulations on the pharmaceutical market were not introduced. Of course
there are other factors influencing the number of prescriptions, such as changes in the morbidity of
the insured. Therefore, these figures cannot serve as proof for our findings, but they support our inter-
pretation.
Source: Own calculation, based on Schwabe U. Arzneiverordnungen 2002 im Überblick.
In: Schwabe U, Paffrath D, editors. Arzneiverordnungs-Report 2003, p. 1.
It is difficult to compare our findings with previous studies because of differences between the study
samples and outcome measures. We chose a more explorative study design and our goal was to deter-
mine the number of patients whose demand patterns changed. Previous literature suggests that in-
creased copayments cause reductions in the number of prescriptions, although the extent of the effect
is small [5-17]. Our results showed small reductions as well: Almost all of those respondents who re-
duced their purchases of prescribed packages (22.6%) waived 1 to 5 packages (82.5%). Effects on
the demand for physician visits influences the number of prescriptions demanded as well. We also
found small reductions in this area. Only 8.6% waived one, and 11.2% waived two or more physician
visits. Further, we found that prescriptions were substituted by OTC products, which is a finding con-
firmed by previous research [20].
Growing effects of copayment on lower income patients were found for the use of antibiotics in the
RAND study [22]. Harris et al. [6] found smaller effects within the four essential drug classes
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Figure 1: Annual Difference in Number of Prescriptions Covered by the Statutory Health Insuran-
ce 1994-2001 in Percent
(antihypertensives, cardiac agents, antidiabetics and thyroid hormones), compared to effects on dis-
cretionary drug classes such as cold remedies and topical anti-inflammatories. This confirms our
findings of smaller effects on the chronically ill.
Our findings have important implications for future health care policy. Results show that increased
copayment not only had a financial impact, but also an impact on drug use. If the government aims to
avoid effects on prescription demand or drug use inequality, copayments have to be reduced to the
previous level or the exemption level has to be raised. From our results, we do not know how a reduc-
tion in physician visits and drug use translates into patient outcomes. For instance, this depends on
whether necessary or unnecessary drugs and services have been avoided. Therefore, further research
needs to be conducted to examine whether copayment levels up to € 6.60 are associated with a re-
duced use of necessary drugs and other necessary health care services in the German population.
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